Skip to Main Content

Paper Details

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
J Neurooncol
3
2022
GBMs, IDH, IDH wild, MGMT, Tumors, glioblastoma, patients, temozolomide, tumor, tumors
Author NameAffiliation
Whitney B PopeDavid Geffen School of Medicine, University of California Los Angeles
Whitney B PopeDavid Geffen School of Medicine, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Noriko SalamonDavid Geffen School of Medicine, University of California Los Angeles
Noriko SalamonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 14

Datasets